Morgan Stanley Oncorus, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.28 - $0.45 $1,088 - $1,749	-3,888 Reduced 46.32%	4,506 $1,000
Q4 2022 Feb 14, 2023	SELL	$0.24 - $0.76 $1,678 - $5,316	-6,995 Reduced 45.45%	8,394 $2,000
Q3 2022 Nov 14, 2022	SELL	$0.85 - $1.65 $23,892 - $46,379	-28,109 Reduced 64.62%	15,389 $13,000
Q2 2022 Oct 27, 2022	SELL	$1.04 - $1.86 $38,804 - $69,400	-37,312 Reduced 46.17%	43,498 $55,000
Q2 2022 Aug 15, 2022	SELL	$1.04 - $1.86 $38,804 - $69,400	-37,312 Reduced 46.17%	43,498 $55,000
Q1 2022 Oct 27, 2022	BUY	$1.44 - $5.62 $53,729 - $209,693	37,312 Added 85.78%	80,810 $143,000
Q1 2022 May 13, 2022	SELL	$1.44 - $5.62 $50,330 - $196,430	-34,952 Reduced 30.19%	80,810 $143,000
Q4 2021 Feb 14, 2022	BUY	$5.03 - $11.63 $193,981 - $448,510	38,565 Added 49.96%	115,762 $611,000
Q3 2021 Nov 15, 2021	BUY	$9.29 - $14.27 $717,160 - $1.1 Million	77,197 New	77,197 $721,000

Ticker ONCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,973,100
Description
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.